Los Angeles Capital Management
AMLX icon

Los Angeles Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Los Angeles Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.52K Sell
325
-527
-62% -$7.41K ﹤0.01% 2155
2025
Q4 		$12K Buy
+852
New +$11.6K ﹤0.01% 2022
2025
Q3 		– Sell
-23,320
Closed -$149K – 1360
2025
Q2 		$149K Buy
+23,320
New +$113K ﹤0.01% 1229

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Los Angeles Capital Management's AMLX Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 62% in Q1 2026, selling an estimated $7.41K and leaving 325 shares worth $4.52K. The position accounts for ﹤0.01% of the portfolio, ranked #2155.

Los Angeles Capital Management first reported a position in AMLX in Q2 2025 and has held it in 3 quarters since. The position peaked at $149K in Q2 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Los Angeles Capital Management held 325 shares of Amylyx Pharmaceuticals worth $4.52K as of Q1 2026.
  • Los Angeles Capital Management sold 527 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $7.41K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #2155 holding.
  • Los Angeles Capital Management first reported a position in Amylyx Pharmaceuticals in Q2 2025 and has held it in 3 quarters since.
  • Los Angeles Capital Management's Amylyx Pharmaceuticals position peaked at $149K in Q2 2025.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.